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Understanding the human gut microbiota has garnered interest from researchers and clinicians
to pharmaceutical companies looking at novel mechanisms to manipulate the microbiota for
the benefit of the host. Studies on the gut microbiota can be loosely characterized into three
areas that include investigating the microbiota’s role in the physiology of the healthy gut, in
the establishment of gastrointestinal disease, and in extra-intestinal manifestations. With deep
sequencing technologies now in routine use in the research environment, novel members of the
gut microbiota are coming to light, and our understanding of this complex ecosystem and its
relationship to the host is slowly improving.
IMPORTANCE OF ERYSIPELOTRICHACEAE IN HUMANS
Reports documenting a potential role for the bacterial family Erysipelotrichaceae, which belongs
to the Firmicutes phylum, in host physiology and/or disease are on the rise. However, more often
than not, these organisms are mentioned in passing, despite the fact that members of this bacterial
family appear to be highly immunogenic and can potentially flourish post-treatment with broad
spectrum antibiotics (Zhao et al., 2013; Palm et al., 2014; Dinh et al., 2015). For example, Palm and
colleagues who developed a method to sort and sequence members of the intestinal microbiota
based on coating with immunoglobulin A (IgA), termed IgA-SEQ, found one member of the
Erysipelotrichaceae to be highly coated by IgA relative to other members of the gut microbiota
(Palm et al., 2014). More recently, Ding and colleagues observed that the relative abundance
of Erysipelotrichi positively correlated with tumor necrosis factor alpha (TNF) levels in a study
investigating patients who had chronic HIV infection and were receiving suppressive antiretroviral
therapy and HIV-uninfected controls (Dinh et al., 2015). Further, Zhao and colleagues found
an increase in the levels of Erysipelotrichaceae incertae sedis in mice treated with high doses of
gentamicin (Zhao et al., 2013).
ERYSIPELOTRICHACEAE AND INFLAMMATION-RELATED
GASTROINTESTINAL DISEASES
The importance of Erysipelotrichaceae in inflammation-related disorders of the gastrointestinal
tract is highlighted by the fact that they have been found to be enriched in colorectal cancer.
For example, their abundance levels were found to be increased in the lumen of colorectal cancer
patients as compared to healthy controls (Chen et al., 2012), and to be significantly higher in the
tumor group of an animal model of 1, 2-dimethylhydrazine-induced colon cancer (Zhu et al., 2014).
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Changes in the levels of Erysipelotrichaceae in patients with
inflammatory bowel diseases (IBD) or animalmodels of IBD have
also been observed; however, the evidence does not appear to
be consistent (Craven et al., 2012; Dey et al., 2013; Gevers et al.,
2014; Labbé et al., 2014; Palm et al., 2014; Schaubeck et al., 2015).
Craven and colleagues identified ileitis-associated shifts toward
Erysipelotrichaceae in C57BL6 mice infected with Toxoplasma
gondii or Giardia muris (Craven et al., 2012), while Schaubeck
and colleagues observed significant increases in the abundance of
Erysipelotrichaceae in mice that develop a TNF-driven Crohn’s
disease (CD)-like transmural inflammation (Schaubeck et al.,
2015). These findings are of interest, given the association
between Erysipelotrichaceae and TNF levels (Dinh et al., 2015).
In contrast, Dey and colleagues found that patients who
experienced recurrence of CD had significantly lower levels of
Erysipelotrichaceae (Dey et al., 2013), and similarly, Gevers and
colleagues found a decreased abundance of Erysipelotrichales
in patients within new-onset CD (Gevers et al., 2014). These
findings are supported by a study by Labbe and colleagues
who analyzed publicly available metagenomic datasets of IBD
patients and controls for bile metabolizing genes, and found
that the abundance of bile salt hydrolase genes originating from
Firmicutes taxa including Erysipelotrichaceae was significantly
reduced in IBD as compared to healthy controls (Labbé et al.,
2014).
These results would suggest inter-host variation, with
inflammatory mouse models having higher levels of
Erysipelotrichaceae, and patients with IBD having lower
levels. Two possible explanations for this include the inherent
differences in the gut microbiota of mice and humans and/or
differences in their innate immune responses upon sensing
bacterial ligands (Zschaler et al., 2014; Nguyen et al., 2015).
However, Palm and colleagues did not observe a significant
difference in the abundance levels of a specific immunogenic
Erysipelotrichaceae species between IBD patients and controls
(Palm et al., 2014). Nonetheless, when the authors infected
germ-free mice with a consortium of bacteria that were classified
as highly coated by IgA (containing Erysipelotrichaceae spp.),
these mice developed a more severe colitis upon treatment
with dextran sodium sulfate than mice colonized by an IgA-
negative consortium of bacteria (Palm et al., 2014). Thus, the
inconsistencies in the results related to IBD could potentially be
attributed to a lack of proper characterization of taxa belonging
to the Erysipelotrichaceae family. For example, species within
Erysipelotrichaceaemay have diverse immunogenicity profiles or
respond differently to inflammation within the gut.
ERYSIPELOTRICHACEAE AND
METABOLIC DISORDERS
Perhaps the strongest evidence for a role for Erysipelotrichaceae
in human disease comes from studies related to metabolic
disorders. Early work on this topic showed a bloom of species
belonging to Erysipelotrichaceae (classified as Mollicutes at the
time of that study) in diet-induced obese animals (Turnbaugh
et al., 2008). In addition, higher levels of Erysipelotrichaceae
in obese individuals (Zhang et al., 2009), and a drop of
approximately 2.5-fold in the abundance of Erysipelotrichaceae
taxa in a hamster model of hypercholesterolemia treated with an
extract to improve cholesterol homeostasis (Martínez et al., 2009)
have been observed. Subsequent studies have confirmed the
association between this bacterial family and lipidemic profiles
within the host. For example, Zhang and colleagues identified
four different lineages within Erysipelotrichaceae to respond
differently to diet or host health phenotypes (Zhang et al.,
2010), while Fleissner and colleagues observed an increase of
Erysipelotrichaceae in mice on high-fat or western diet (Fleissner
et al., 2010). Further, Spencer and colleagues showed that the
abundance of Erysipelotrichi were positively associated with
changes in liver fat in female subjects who were placed on diets
in which choline levels were manipulated (Spencer et al., 2011).
More recently, in an important study examining the
microbiota of hamsters whose cholesterol metabolism was
modulated using dietary plant sterol esters, Martinez and
colleagues provided strong evidence for a correlation between
the levels of Erysipelotrichaceae and host cholesterol metabolites
(Martínez et al., 2013). In addition to this, Etxeberria and
colleagues observed that supplementation of the flavonol
quercetin inhibited the growth of Erysipelotrichaceae (Etxeberria
et al., 2015), which is particularly interesting given that flavonoids
have been suggested to assist in weight loss (Hurt and Wilson,
2012).
NUTRITION STUDIES PROVIDE FURTHER
INSIGHTS INTO THE ROLE OF
ERYSIPELOTRICHACEAE IN THE GUT
Nutrition studies further support the influence of dietary
fat on the abundance of Erysipelotrichaceae. Harris and
colleagues identified an accumulation of a specific taxon within
Erysipelotrichaceae in mice with liver injury associated with
parenteral nutrition, and observed a marked reduction in liver
injury also corresponding to a decrease in the abundance of
the same Erysipelotrichaceae taxon following antibiotic treatment
(Harris et al., 2014). The authors determined that the fluctuations
in abundance of Erysipelotrichaceae corresponded to the soy
oil based-lipid emulsion from the parenteral nutrition solution
(Harris et al., 2014).
In support of these findings, our group has recently observed
a decrease in the abundance of Erysipelotrichaceae in CD patients
undergoing low-fat (∼13.5 g/1000Kcal; Nahidi et al., 2013)
exclusive enteral nutrition (EEN) therapy (Kaakoush et al., 2015).
This is of interest when taken together with the findings of Li
and colleagues who showed that EEN therapy was associated with
a significant decrease in visceral fat area in patients with CD
(Li et al., 2014). Indeed, Gassull and colleagues have concluded
that the type of dietary fat may be important for the efficacy of
enteral nutrition in CD (Gassull et al., 2002). Given this, it is
no surprise that IBD patients often exhibit differences in their
levels of cholesterol as compared to healthy subjects (Agouridis
et al., 2011), and infliximab maintenance therapy targeting TNF
in CD patients, leads to an increase in cholesterol levels and a
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FIGURE 1 | Potential role for Erysipelotrichaceae in inflammation within the host.
significant increase in abdominal fat tissue (Parmentier-Decrucq
et al., 2009). With all the above evidence in mind, the fluctuations
in Erysipelotrichaceae levels in IBD patients are likely to be
associated with patient lipid or cholesterol phenotypes and/or
patient diet, but may still have a significant impact on disease
presentation and/or activity (Figure 1).
CONCLUSIONS
Taken together, there is strong evidence supporting an
association between Erysipelotrichaceae and host lipid
metabolism, warranting additional investigation into the
metabolic profiles of these organisms, and the influence they
have on the host. Partial loss of fatty acid biosynthesis has been
reported in the genomes of some members of Erysipelotrichaceae
(e.g., Erysipelothrix rhusiopathiae; Kwok et al., 2014); thus,
it would be of interest to determine if these metabolic
characteristics have any impact on their role within the host.
Further, the finding that specific taxa within Erysipelotrichaceae
may be correlated to inflammation (Dinh et al., 2015), while
others are highly immunogenic (Palm et al., 2014) adds weight to
the importance of properly characterizing this bacterial family,
and may eventually provide promising microbial targets to
combat metabolic disorders. It is worth noting, however, that
current evidence associating this bacterial family with disease is
correlative, and studies examining the direct impact that changes
in the abundance of Erysipelotrichaceae have on the host are
required.
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